Evidence map›Paper›PMID 29734652›Full record

ArticleInternational journal of molecular sciences2018

Antimalarial Activity of Orally Administered Curcumin Incorporated in Eudragit

Elisabet Martí Coma-Cros, Arnau Biosca, Elena Lantero, Maria Letizia Manca, Carla Caddeo, Lucía Gutiérrez, Miriam Ramírez, Livia Neves Borgheti-Cardoso, Maria Manconi, Xavier Fernàndez-Busquets

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Current State of Scientific Knowledge on Curcumin Encapsulation and Applications.Recent advances in food, nutrition & agriculture · 2025
    Review
  4. Preparation andPharmaceutical nanotechnology · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Curcumin effect onPeerJ · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elisabet Martí Coma-CrosNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain. elisabet.marti@isglobal.org.
Arnau BioscaNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain. abiosca@ibecbarcelona.eu.ORCID 0000-0002-3047-8991
Elena LanteroNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain. elantero@ibecbarcelona.eu.
Maria Letizia MancaDepartment of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy. mlmanca@unica.it.ORCID 0000-0002-3787-257X
Carla CaddeoDepartment of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy. caddeoc@unica.it.
Lucía GutiérrezNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain. lucia.gutierrez@isglobal.org.
Miriam RamírezNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain. miriam.ramirez@isglobal.org.
Livia Neves Borgheti-CardosoNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain. lborgheti@ibecbarcelona.eu.ORCID 0000-0002-9655-8214
Maria ManconiDepartment of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy. manconi@unica.it.ORCID 0000-0003-4818-2344
Xavier Fernàndez-BusquetsNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain. xfernandez_busquets@ub.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin is an antimalarial compound easy to obtain and inexpensive, having shown little toxicity across a diverse population. However, the clinical use of this interesting polyphenol has been hampered by its poor oral absorption, extremely low aqueous solubility and rapid metabolism. In this study, we have used the anionic copolymer Eudragit

Indexed as

Drug Delivery SystemsAdministration, OralAnimalsAntimalarialsCurcuminHumansLiposomesMalariaMiceNanoparticlesPlasmodium yoeliiAntimalarialsCurcuminLiposomescurcuminEudragithyaluronanlipid nanovesiclesmalariananomedicineNutrioseoral administrationPlasmodium yoelii

Identifiers

PMID29734652
PMCPMC5983818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.